Agache, I., Beltran, J., Akdis, C., Akdis, M., Canelo‐Aybar, C., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Del Giacco, S., Eiwegger, T., Firinu, D., Gern, J. E., Hamelmann, E., Hanania, N., Mäkelä, M., Hernández‐Martín, I., Nair, P., O'Mahony, L., Papadopoulos, N. G., Papi, A., Park, H., Pérez de Llano, L., Posso, M., Rocha, C., Quirce, S., Sastre, J., Shamji, M., Song, Y., Steiner, C., Schwarze, J., Alonso‐Coello, P., Palomares, O., & Jutel, M. (2020). efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy, 75(5), 1023–1042. http://access.bl.uk/ark:/81055/vdc_100103795644.0x00003f